All Updates

All Updates

icon
Filter
Partnerships
Takeda and Ascentage Pharma partnered for exclusive rights to leukemia treatment olverembatinib
Precision Medicine
Jun 14, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 14, 2024

Takeda and Ascentage Pharma partnered for exclusive rights to leukemia treatment olverembatinib

Partnerships

  • Takeda has entered an option agreement with Ascentage Pharma to exclusively license olverembatinib, a therapy for chronic myeloid leukemia and other blood cancers.

  • Should the option be exercised, Takeda may get global rights to develop and market olverembatinib outside Mainland China and certain other territories. In return, Ascentage would receive a USD 100 million upfront payment and a minority equity investment from Takeda plus potential milestone payments and royalties upon successful regulatory approval. Ascentage will continue to oversee the clinical development of olverembatinib, which is in Phase III trials.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.